Summary
This 8-K filing from BeiGene, Ltd. (ONC) on September 24, 2018, provides an update on the company's clinical development progress through press releases issued on September 20th and 21st. The company presented preliminary results from Chinese patient trials at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO). The focus was on two key investigational drugs: tislelizumab, an anti-PD-1 antibody, and zanubrutinib, a BTK inhibitor. Investors should note the preliminary data presented for tislelizumab in patients with MSI-H/dMMR solid tumors and in Chinese patients with lung cancers, as well as preliminary results for zanubrutinib in Chinese patients with B-cell lymphoma. These presentations at a significant oncology conference highlight ongoing clinical trials and potential pipeline advancements for BeiGene within the Chinese market.
Key Highlights
- 1BeiGene presented preliminary results for its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with MSI-H or dMMR solid tumors at the CSCO meeting.
- 2Preliminary clinical data on tislelizumab in Chinese patients with lung cancers was also presented at the CSCO meeting.
- 3The company announced preliminary results from a Phase 1 trial of its BTK inhibitor, zanubrutinib, in Chinese patients with B-cell lymphoma at the CSCO meeting.
- 4All presentations were based on oral presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China.
- 5The press releases detailing these results are filed as exhibits to this Form 8-K.
- 6The filing date of this report is September 24, 2018, with press releases dated September 20 and 21, 2018.